Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Combined With Bupivacaine for Erector Spinae Plane Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* elective posterior lumbosacral spine fixation and fusion surgery due to different causes that diagnosed clinically and radiologically including MRI and Plain X ray~Exclusion Criteria:~* hypersensitivity to the drugs used in the study \[local anesthetics, non-steroidal anti-inflammatory drugs, opioids and the drug under investigation (dexmedetomidine)\]~* patients with any contraindication to regional anesthesia as skin infections at the site of the block~* history of bleeding disorders or receiving anticoagulant medications

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine combined with bupivacaine group (DB group) (Type: ACTIVE_COMPARATOR): patients received 1ug/kg dexmedetomidine plus 20 mL of bupivacaine 0.25%,
- bupivacaine 0.25%, (Type: ACTIVE_COMPARATOR): patients received 20 ml of bupivacaine 0.25%
- control group (S group) (Type: PLACEBO_COMPARATOR): patients received 20 ml of normal saline 0.9%.

Based on this trial design, predict the completion outcome and termination type (if applicable).